146 related articles for article (PubMed ID: 16684431)
1. Initial experience with teriparatide in the United States.
Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
[TBL] [Abstract][Full Text] [Related]
2. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
3. Patient experience with a new teriparatide delivery device.
Dore RK; Feldman RG; Taylor KA; See K; Dalsky GP; Warner MR
Curr Med Res Opin; 2009 Oct; 25(10):2413-22. PubMed ID: 19656016
[TBL] [Abstract][Full Text] [Related]
4. Treating osteoporosis with teriparatide: many unknowns?
Shukla VK
Issues Emerg Health Technol; 2003 Nov; (51):1-4. PubMed ID: 14610756
[TBL] [Abstract][Full Text] [Related]
5. Teriparatide: new indication. During corticosteroid therapy: no fewer clinical fractures. Unnecessarily inconvenient.
Prescrire Int; 2009 Aug; 18(102):159. PubMed ID: 19743573
[No Abstract] [Full Text] [Related]
6. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
7. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
Tashjian AH; Gagel RF
J Bone Miner Res; 2006 Mar; 21(3):354-65. PubMed ID: 16491282
[No Abstract] [Full Text] [Related]
8. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M
Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
10. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
Sowa H; Hamaya E; Yamamoto T
Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
[TBL] [Abstract][Full Text] [Related]
11. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
Lems WF; Hamdy NA; Netelenbos JC
Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
[TBL] [Abstract][Full Text] [Related]
12. Teriparatide for severe osteoporosis.
Cappuzzo KA; Delafuente JC
Ann Pharmacother; 2004 Feb; 38(2):294-302. PubMed ID: 14742769
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
14. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
Hanley DA; Zhang Q; Meilleur MC; Mavros P; Sen SS
Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
16. The teriparatide in the treatment of severe senile osteoporosis.
Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
[TBL] [Abstract][Full Text] [Related]
17. Combined use of teriparatide and TNFalpha blockade: safety.
Migliore A; Massafra U; Capuano A; Martin SM
Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):18-20. PubMed ID: 18180602
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.
Nishikawa A; Ishida T; Taketsuna M; Yoshiki F; Enomoto H
Clin Interv Aging; 2016; 11():913-25. PubMed ID: 27462147
[TBL] [Abstract][Full Text] [Related]
20. [Evidence for osteoporosis treatment using PTH (1-34) daily subcutaneous injection].
Yamamoto T; Hamaya E; Sowa H
Clin Calcium; 2012 Mar; 22(3):399-406. PubMed ID: 22370307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
